Healthrageous, United BioSource And Boehringer Ingelheim Launch SMART Digital Diabetes Study

Healthrageous, United BioSource And Boehringer Ingelheim Launch SMART Digital
                                Diabetes Study

PR Newswire

BOSTON and INGELHEIM, Germany, July 16, 2013

BOSTON and INGELHEIM, Germany, July 16, 2013 /PRNewswire/ --Healthrageous,
Inc., a digital health management company, and Boehringer Ingelheim, announced
today that Healthrageous has launched the SMART Study together with United
BioSource Corporation (UBC) to evaluate a digital technology enabled
self-management solution to potentially improve the health status of people
with Type 2 diabetes. The goal of the solution is to leverage technology in a
way that makes the personalized journey of self-managing diabetes easier for
patients to self-manage their disease.

Through this Institutional Review Board (IRB) approved research project,
adults who have been diagnosed with Type 2 diabetes for at least six months
will have access to Healthrageous' digital diabetes self-management program.
The web and smartphone delivered program will include a personalized action
plan with health behavior improvement goals, a wireless glucose meter
transmitting data to clinical monitors, as well as HbA1c at-home test kits. By
combining medical claims data, this collaboration will allow an evaluation of
the impact a digital diabetes platform could have on medical and
pharmaceutical costs, clinical care, consumer behavior modification and device
and self-reported biometric health measures.

UBC will identify and help manage the recruitment of participants from nearly
a dozen large U.S. employers for the study.

"Through a truly innovative, patient-centric design, this study will allow us
to collect and integrate patient-reported data, biometric data and claims data
in order to generate new insights into health behaviors, outcomes and cost
utilization," said Abbe Steel, Vice President, Patient & Physician Services,

"Innovations in machine learning and technology offer the opportunity to
create and deliver a unique experience for each person with Type 2 diabetes,"
said Rick Lee, President and CEO, Healthrageous. "We are delighted to be
working with Boehringer Ingelheim and UBC on this first-of-its-kind evaluation
of the promise that digital technology holds in stemming the Type 2 diabetes

"Boehringer Ingelheim is committed to innovation in diabetes treatment and
strives for solutions that offer a 'beyond pill' approach in health care,"
said Klaus Wilgenbus, SVP, PM, Business Development, Licensing & Strategy at
Boehringer Ingelheim. "As part of our ongoing collaboration with
Healthrageous, this project adds nicely to our goal to provide and develop
solutions for patients and their families that contribute to a more holistic
way of diabetes treatment."

About Healthrageous
Healthrageous, Inc. is an Accountable Health company that supports individual
journeys to prevent and self-manage chronic health conditions via the web and
a mobile app. It achieves superior engagement through its proprietary platform
that incorporates personalized goal setting, health journey maps with gaming
dynamics, timely biometric feedback and interactive digital coaching. The
digital coach leverages multiple tools such as inspirational messages,
recognition and incentives, challenges, social networking, trackers and
reminders, and interactive educational content.

The company's solutions are based on technologies developed at the Center for
Connected Health, a division of Partners HealthCare, founded by Brigham and
Women's Hospital and Massachusetts General Hospital, teaching affiliates of
Harvard Medical School. Connect:, Twitter and LinkedIn.

About UBC
United BioSource Corporation (UBC), a subsidiary of Express Scripts Holding
Company, leads the market in providing integrated, comprehensive clinical,
safety, and commercialization services. Working with Express Scripts'
specialty pharmacy and specialty distribution organizations, UBC is uniquely
positioned to seamlessly integrate best-in-class services throughout the
lifecycle of a product.

UBC brings together renowned scientific research and operations experts with
leading-edge technologies, allowing for the best patient and healthcare
provider experience.

Comprehensive, end-to-end services cover product and patient population
characterization during development and market entry, as well as a focus on
the patient experience, safety, and adherence. For more information, visit or follow @UBCPharma on Twitter.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 140
affiliates in 50 countries and more than 46,000 employees. Since it was
founded in 1885, the family-owned company has been committed to researching,
developing, manufacturing and marketing novel medications of high therapeutic
value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture.
Involvement in social projects, caring for employees and their families, and
providing equal opportunities for all employees form the foundation of the
global operations. Mutual cooperation and respect, as well as environmental
protection and sustainability are intrinsic factors in all of Boehringer
Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about €14.2 billion. R&D
expenditure in the business area Prescription Medicines corresponds to 22.5%
of its net sales. For more information, go to

SOURCE Healthrageous, Inc.

Contact: Gina Cella, Healthrageous, t: 781-334-4692,; or Ralph Warsinsky, Boehringer Ingelheim GmbH,
t: +49 6132 77 7051,
Press spacebar to pause and continue. Press esc to stop.